RxDoctor Payments Data

Raquel Moncrieffe

Optometrist · Richmond, VANPI 1679513022

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $15,794 of the $17,545 with a category attached, or 90.0%. Optos, Inc. accounts for 90.1% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $16,074, more than ten times the $404 reported in 2019. Among optometrist clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$17,545in general payments, 2019–2025

Across 48 payments — averaging $365.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optos, Inc.$16K
  • Sun Pharmaceutical Industries Inc.$392
  • Amgen$218
  • Johnson & Johnson Vision Care, Inc.$209
  • AbbVie$183
  • Dompe US, Inc.$108
  • plus $623 from 10 others

What the payments were for

  • Speaking & faculty fees$15,79490%
  • Food & beverage$1,75110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,545 in reported general payments places this provider in the 95th percentile of 1,230 optometrist providers in Virginia.

See all optometrist providers in Virginia

Medicare billing

Part B allowed, 2024
$129,412
Medicare patients
817
Services billed
1,290

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast15$13,864
LumiganBimatoprost18$7,830
Brimonidine Tartrate15$2,711
Latanoprost91$1,439
Prednisolone Acetate31$1,241
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha106$1,182
Timolol Maleate35$409
MoxifloxacinMoxifloxacin Hcl17$331
ErythromycinErythromycin Base37$304
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat20$210
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav11$58

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$20$13,86415 claims
AbbVieLumigan$183$7,83018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,230 optometrist providers in Virginia.

Other optometrist in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →